Executive Profile

Kevin P. Starr Chairman and Partner, Afferent Pharmaceuticals, Inc.

Age	Total Calculated Compensation	This person is connected to 8 Board Members in 8 different organizations across 12 different industries. See Board Relationships
49	--

Background

Mr. Kevin P. Starr serves as the Chairman and is Partner at Afferent Pharmaceuticals, Inc. Mr. Starr co-founded Third Rock Ventures, LLC in 2007 and is its Partner. He serves as an Interim Chief Executive Officer and Director at Sage Therapeutics, Inc. He focuses on the formation, development, and business strategy of Therapeutics’ portfolio companies as well as actively identifying and evaluating new investments. He assumes active leadership roles in the portfolio companies, ... functioning as the Chief Executive Officer through the first 12 to 18 months post launch. Mr. Starr is a founding investor in Prospect Pictures. He served as the Chief Financial Officer of Cytomed, Inc. He is a proven operational leader with over 25 years of experience in building, operating, and management of finance, technology, and operations in biotechnology companies. Prior to this, Mr. Starr was the Chief Operating Officer from December 2001 to December 2002 and Chief Financial Officer from December 1998 to December 2002 at Millennium Pharmaceuticals, Inc. At Millennium Pharmaceuticals, he led key roles in raising billions of dollars in capital through strategic alliances and public financing and driving growth through company expansion and mergers and acquisitions. Mr. Starr served as an Interim Chief Executive Officer at Agios Pharmaceuticals, Inc. until August 2009 and ZafGen Pharmaceuticals. He served as a Vice President of Finance at Millennium BioTherapeutics from March 1998 to December 1998. Mr. Starr was a Corporate Controller and Head of Finance at Biogen Idec Ma Inc. from 1991 to February 1998. He was also the Chief Financial Officer at ChemGenics Pharmaceuticals, Inc. Mr. Starr served in various executive roles at Digital Equipment Corporation. He has been a Director of Alnylam Pharmaceuticals, Inc. since September 2003. He serves as a Director of Zafgen, Inc., Zafgen Pharmaceuticals, Global Blood Therapeutics, Inc., Cambridge Savings Bank, Afferent Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., MyoKardia, Inc. and PanOptica, Inc. Mr. Starr served as an Independent Director at Konarka Technologies, Inc. and Human Genome Sciences Inc. from October 2006 to August 29, 2007. He was also a Director of Vitae Pharmaceuticals, Inc. Mr. Starr received an M.S. in Corporate Finance from Boston College and a B.A. in Mathematics and Business from Colby College.

Corporate Headquarters 2755 Campus Drive San Mateo, California 94403 United States Phone: 650-286-1276 Fax: 650-286-1833 Board Members Memberships Former Independent Director Konarka Technologies, Inc. Former Director Vitae Pharmaceuticals, Inc. Director Zafgen, Inc. Director Agios Pharmaceuticals, Inc. Chairman and Partner Afferent Pharmaceuticals, Inc. Director PanOptica, Inc. Interim Chief Executive Officer and Director Sage Therapeutics, Inc Director Global Blood Therapeutics, Inc. Director MyoKardia, Inc. 2003-Present Director, Chairman of Audit Committee and Member of Compensation Committee Alnylam Pharmaceuticals, Inc. 2006-2007 Former Independent Director and Member of Audit Committee Human Genome Sciences Inc. Education MS Boston College BA Colby College Other Affiliations Biogen Idec Ma Inc. ChemGenics Pharmaceuticals, Inc. Cytomed, Inc. Human Genome Sciences Inc. Millennium Pharmaceuticals, Inc. Konarka Technologies, Inc. Vitae Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. Boston College Colby College Zafgen, Inc. Third Rock Ventures, LLC Agios Pharmaceuticals, Inc. PanOptica, Inc. Third Rock Ventures II, L.P. Sage Therapeutics, Inc Global Blood Therapeutics, Inc. MyoKardia, Inc.

Annual Compensation There is no Annual Compensation data available. Stocks Options There is no Stock Options data available. Total Compensation There is no Total Compensation data available.

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.